The HNRNPLL Knockout HeLa Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population designed to abolish functional HNRNPLL expression in a HeLa background. This heterogeneous pool comprises cells carrying independent disruptions at the HNRNPLL locus, providing a robust loss-of-function model while minimizing clonal selection artifacts. The polyclonal format is particularly suited for assessing global impacts on alternative splicing and post-transcriptional regulation, capturing a spectrum of editing outcomes that reflect the overall cellular response to HNRNPLL depletion.
The host HeLa cell line originates from a cervical adenocarcinoma of Henrietta Lacks and is stably positive for human papillomavirus type 18 (HPV18). HeLa cells express the viral oncoproteins E6 and E7, which inactivate the tumor suppressors p53 and retinoblastoma protein, respectively, driving an immortalized and highly proliferative phenotype. As one of the most widely characterized human cell lines, HeLa offers a genetically tractable and well-annotated platform for studying gene function, particularly within the context of cervical cancer biology where splicing dysregulation is increasingly recognized.
HNRNPLL encodes a heterogeneous nuclear ribonucleoprotein that binds pre-mRNA and modulates splice site selection through interactions with core spliceosome constituents. Key interacting partners include U1 snRNP, U2 snRNP, SF1, and U2AF, and the protein collaborates with other hnRNP family members to orchestrate exon inclusion or skipping. A critical downstream target is PTPRC (CD45), where HNRNPLL regulates alternative splicing to generate isoforms with distinct signaling capacities; however, its regulon extends to numerous other pre-mRNAs implicated in cell proliferation, adhesion, and apoptosis. Knockout of HNRNPLL disrupts these regulatory networks, yielding widespread splicing alterations and isoform switching that can be systematically interrogated.
Within the HeLa cervical adenocarcinoma model, HNRNPLL ablation permits dissection of splicing-dependent mechanisms underlying cancer hallmarks. The HPV18-positive environment introduces additional dimensionality, as viral oncoproteins may intersect with host splicing machinery, and loss of HNRNPLL can reveal context-specific vulnerabilities. Researchers can employ this system to investigate whether HNRNPLL-controlled splicing events influence malignant traits such as uncontrolled proliferation, resistance to apoptosis, or metastatic potential, offering translational insights into HPV-associated malignancies.
These polyclonal knockout cells support a comprehensive suite of downstream assays. RNA-seq enables transcriptome-wide splicing analysis, while RT-qPCR allows quantification of specific isoform changes. Knockout efficiency can be verified by Western blotting, and immunofluorescence permits visualization of splicing factor localization. Co-immunoprecipitation coupled with mass spectrometry facilitates identification of protein interaction networks. Applications span alternative splicing research, cancer cell biology, RNA-binding protein functional studies, and high-throughput pharmacological screening. For additional technical details, please contact Ascent Research.
